Want to see SE:NXTCL full AI Analyst Report?
NextCell Pharma AB (NXTCL) Stock Statistics & Valuation Metrics
Total Valuation
NextCell Pharma AB has a market cap or net worth of SEK 29.07M. The enterprise value is SEK 97.59M.
- Market Cap
- SEK 29.07M
- Enterprise Value
- SEK 97.59M
Share Statistics
NextCell Pharma AB has 126,392,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 126,392,960
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
NextCell Pharma AB’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -50.31%.
- Return on Equity (ROE)
- -0.53
- Return on Assets (ROA)
- -0.46
- Return on Invested Capital (ROIC)
- -50.31%
- Return on Capital Employed (ROCE)
- -0.50
- Revenue Per Employee
- 455.72K
- Profits Per Employee
- -1.46M
- Employee Count
- 24
- Asset Turnover
- 0.14
- Inventory Turnover
- 85.85
Valuation Ratios
The current PE Ratio of NextCell Pharma AB is -0.60. NextCell Pharma AB’s PEG ratio is -0.01.
- PE Ratio
- -0.60
- PS Ratio
- 2.88
- PB Ratio
- 0.62
- Price to FCF
- -0.50
- Price to Operating Cash Flow
- -0.55
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, NextCell Pharma AB had revenue of 10.94M and earned -35.14M in profits. Earnings per share was -0.46.
- Revenue
- 10.94M
- Gross Profit
- -35.87M
- Operating Income
- -35.87M
- Pretax Income
- -35.14M
- Net Income
- -35.14M
- EBITDA
- -32.63M
- Earnings Per Share (EPS)
- -0.46
Cash Flow
In the last 12 months, operating cash flow was -52.97M and capital expenditures -4.74M, giving a free cash flow of -57.71M billion.
- Operating Cash Flow
- -52.97M
- Free Cash Flow
- -57.71M
- Free Cash Flow per Share
- -0.46
Dividends & Yields
NextCell Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -200.09%
- Earnings Yield
- -138.83%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- -74.36%
- 50-Day Moving Average
- 0.98
- 200-Day Moving Average
- 1.14
- Relative Strength Index (RSI)
- 17.06
- Average Volume (3m)
- 643.72K
Important Dates
NextCell Pharma AB upcoming earnings date is Nov 26, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Oct 22, 2026
- Next Earnings Date
- Nov 26, 2026
- Ex-Dividend Date
- ―
Financial Position
NextCell Pharma AB as a current ratio of 10.02, with Debt / Equity ratio of 0.00%
- Current Ratio
- 10.02
- Quick Ratio
- 9.92
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.19
- Interest Coverage Ratio
- -13802.15
Taxes
In the past 12 months, NextCell Pharma AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NextCell Pharma AB EV to EBITDA ratio is -0.18, with an EV/FCF ratio of -0.13.
- EV to Sales
- 0.77
- EV to EBITDA
- -0.18
- EV to Free Cash Flow
- -0.13
- EV to Operating Cash Flow
- -0.15
Balance Sheet
NextCell Pharma AB has SEK 21.09M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 21.09M billion.
- Cash & Marketable Securities
- SEK 21.09M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 21.09M
- Net Cash Per Share
- SEK 0.17
- Tangible Book Value Per Share
- SEK 0.37
Margins
Gross margin is -447.56%, with operating margin of -447.56%, and net profit margin of -440.78%.
- Gross Margin
- -447.56%
- Operating Margin
- -447.56%
- Pretax Margin
- -440.78%
- Net Profit Margin
- -440.78%
- EBITDA Margin
- -420.80%
- EBIT Margin
- -445.53%
Analyst Forecast
The average price target for NextCell Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -4.02%
- EPS Growth Forecast
- 35.86%
Scores
- Smart Score
- ―
- AI Score
- 49
